Cutler Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Cutler Group’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,100	Closed	-$5K	–	5661
2022 Q2	$5K	Sell	1,100 -2,700	-71%	-$41.6K	﹤0.01%	3782
2022 Q1	$5K	Buy	3,800 +2,600	+217%	+$39.4K	﹤0.01%	4198
2021 Q4	$1K	Buy	+1,200	New	+$20K	﹤0.01%	5214
2018 Q3	–	Sell	-2,000	Closed	-$14K	–	4827
2018 Q2	$14K	Hold	2,000	–	–	﹤0.01%	2451
2018 Q1	$12K	Buy	+2,000	New	+$64.3K	﹤0.01%	2681
2016 Q3	–	Sell	-500	Closed	-$3K	–	7514
2016 Q2	$3K	Sell	500 -1,600	-76%	-$28.3K	﹤0.01%	5464
2016 Q1	$45K	Sell	2,100 -1,100	-34%	-$22.4K	﹤0.01%	2448
2015 Q4	$40K	Buy	+3,200	New	+$111K	﹤0.01%	2706

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cutler Group's RVNC Position: Q1 2023 in Review

Cutler Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 4,760 shares — an estimated $87K sold.

Cutler Group first reported a position in RVNC in Q4 2015 and held it in 20 quarters. The position peaked at $230K in Q4 2015. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

Cutler Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 4,760 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $87K.
Cutler Group first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 20 quarters.
Cutler Group's Revance Therapeutics, Inc. position peaked at $230K in Q4 2015.
216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.